February 2012

Kiestra Lab Automation BV

BD acquires KIESTRA Lab Automation BV

Learn more

October 2012


BD acquires Neomend

Learn more

December 2012

Safety Syringes

BD acquires Safety Syringes

Learn more

March 2013

Cato Software Solutions

BD acquires Cato Software Solutions

Learn more

August 2013

Sirigen Group

BD acquires Sirigen Group 

Learn more

October 2013


BD acquires Medafor

Learn more

November 2013

Rochester Medical

BD acquires Rochester Medical

Learn more

January 2014


BD Acquires Alverix

Learn more

October 2014

GenCell Biosytems

BD acquires GenCell Biosystems

Learn more

March 2015


BD acquires CareFusion

Learn more

march 2015

CRISI Medical Systems

BD acquires CRISI Medical Systems

Learn more

August 2015

Cellular Research

BD acquires Cellular Research

Learn more

November 2015


BD acquires Medicon

Learn more

January 2016

Liberator Medical

BD acquires Liberator Medical

Learn more

April 2017

Caesarea Medical Electronics

BD acquires Caesarea Medical Electronics

Learn more

Deember 2017

C.R. Bard

BD acquires C.R. Bard

Learn more

July 2018

TVA Medical

BD acquires TVA Medical

Learn more


Mergers and acquisitions (M&A) serve as an integral tool for BD in advancing its strategy of improving patient outcomes, reducing the cost of care, expanding access and enhancing the operations of our customers around the world. In recent years BD has completed dozens of tuck-in acquisitions including  TVA Medical, Medafor, and Kiestra Lab Automation, and we continue to seek out attractive opportunities which align with the strategies of BD’s businesses and regions.

BD has developed leading capabilities in transactional structuring, execution, due diligence and integration. BD's Corporate Development team partners with our businesses, functions and regions to evaluate potential opportunities. All M&A opportunities should be directed to our Corporate Development team based out of our global headquarters in Franklin Lakes, New Jersey, USA through the website submission form.

BD examines and executes on M&A opportunities that are financially attractive and aligned with our strategy. This has proven to be, and remains, an important lever as we pursue our purpose of Advancing the World of Health— Vince Forlenza, Chairman

M&A Criteria

BD seeks inorganic opportunities that advance our long-term strategy through increasing patient access, driving better outcomes, managing system cost pressures, and improving health care safety. Directional criteria is provided below:

  • Differentiated technologies
  • Attractive underlying market growth
  • Global reach and application
  • Digital and connected devices / solutions
  • Vascular access management
  • Medication management
  • Immunology research and testing
  • Infectious disease diagnostics and management
  • Chronic disease management (diabetes, PAD, ESRD)
  • Surgical procedures and urological disorders

Submit an opportunity

Submit an acquisition opportunity to BD now Submit opportunity